FDA-Approved, Safe & Targeted Treatment for Neuroendocrine Tumors
Lutetium-177/Ac-225 DOTATATE Therapy in Bangalore
Experience advanced, personalized theranostic care with Lutathera — a scientifically proven therapy designed for somatostatin receptor–positive neuroendocrine tumors.
About Lutathera (Lu-177 DOTATATE) Therapy
At our advanced Theranostics center in Bangalore, we provide Lutetium-177 DOTATATE (Lutathera) — an FDA-approved therapy for treating advanced and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Lutathera is a cutting-edge targeted radionuclide therapy used to treat somatostatin receptor–positive NETs. It combines:
- DOTATATE, which binds to neuroendocrine tumor cells
- Lutetium-177, a radioactive isotope that emits therapeutic radiation
FDA-Approved for the treatment of metastatic or inoperable, progressive GEP-NETs
Clinically safe and well-tolerated, based on global clinical trials
Patient Eligibility for Lutathera
How Does Lutathera Work
Conditions Treated with Lutathera
01. Midgut Neuroendocrine Tumors
These tumors arise in the small intestine (midgut) and often spread to the liver. They usually express somatostatin receptors, making them highly responsive to Lutathera therapy.
02. Pancreatic NETs
These are hormone-producing tumors that develop in the pancreas. When they show somatostatin receptor positivity, Lutathera can effectively target and control their growth.
03. Other Somatostatin Receptor–Positive Tumours
This includes any tumors (lung carcinoid, meningioma, merkel cell carcinoma, insulinoma, hemangiopericytoma, breast cancers) that shows uptake on a Ga-68 DOTATATE PET/CT scan. Such tumors have receptors that Lutathera can bind to, enabling precise and targeted treatment.
Why Choose Our Theranostics Center
Frequently Asked Question
Subsribe To Our Newsletter
Stay in touch with us to get latest news at Theranostic